Alphyn Biologics Announces Enrollment Passes Halfway Point in Phase2a Clinical Trial of Mild-to-Moderate Atopic Dermatitis Treatment

/PRNewswire/ -- Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that enrollment in...

Related Keywords

Neal Koller ,Joana Geoghegan ,Timothyj Foster ,Aland Irvine ,Prnewswire Alphyn Biologics ,Shalini Gupta ,Angel Physicians Fund ,Atopic Dermatitis ,Alphyn Biologics ,